

Page 1

=> d his

(FILE 'HOME' ENTERED AT 16:42:46 ON 28 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:42:58 ON 28 MAY 2003

L1 STRUCTURE UPLOADED


L2 47 L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 16:43:26 ON 28 MAY 2003

L3 4 L2

=> d que stat 13

L1 STR



G1 CH2, Et

Structure attributes must be viewed using STN Express query preparation.

L2 47 SEA FILE=REGISTRY SSS FUL L1

L3 4 SEA FILE=CAPLUS ABB=ON PLU=ON L2

=> d 13 total ibib abs hitstr

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:927275 CAPLUS

DOCUMENT NUMBER: 138:11420

TITLE: An adenosine A2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

INVENTOR(S): Yeadon, Michael; Armstrong, Roisin A.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096462	A1	20021205	WO 2002-EP5725	20020524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

28/05/2003<L> 16:45

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-293842 ^P P 20010525
 GB 2001-29275 A 20011206
 GB 2002-10238 A 20020503

AB The present invention relates to a combination of a selective adenosine A2a receptor agonist and an anticholinergic agent for simultaneous, sequential or sep. administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.

IT **383887-24-9**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A2a agonists and anticholinergic agent in combination for treating obstructive airways diseases)

RN 383887-24-9 CAPLUS

CN Adenosine, 2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:905869 CAPLUS

DOCUMENT NUMBER: 138:8333

TITLE: Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
 INVENTOR(S): Yeadon, Michael; Armstrong, Roisin Anne; Watson, John W.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094273	A2	20021128	WO 2002-EP5764	20020525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003013675	A1	20030116	US 2002-154561	20020524
PRIORITY APPLN. INFO.:			US 2001-293530P	P 20010525
			US 2001-303934P	P 20010709

OTHER SOURCE(S): MARPAT 138:8333

AB A combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprises (i) an adenosine A2A receptor agonist, and (ii) an anticholinergic agent, administered sep., simultaneously or sequentially by inhalation. The preferred anticholinergic agent component is tiotropium bromide. For example, a pressurized, tetrafluoroethylene-coated aluminum canister for use in a metered dose inhaler was prepared, sufficient to provide about 200 actuations of the inhaler, each actuation providing about 20 µg of each active ingredient. The contents of each the canister were:

N-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(methoxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl]methyl]-2-phenylacetamide, tiotropium bromide, dichlorotetrafluoroethane, trichloromonofluoromethane, dichlorodifluoromethane, and soya lecithin.


IT 383887-24-9 383887-26-1 383887-28-3
 383887-30-7 383887-93-2 476644-87-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of adenosine A2A-receptor agonist and anticholinergic agent for treating obstructive airways and other inflammatory diseases)

RN 383887-24-9 CAPLUS

CN Adenosine, 2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-26-1 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[2-(1-piperidiny)ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-28-3 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-30-7 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-93-2 CAPLUS

CN Adenosine, N-[2,2-bis(4-chlorophenyl)ethyl]-2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 476644-87-8 CAPLUS

CN Adenosine, 2-[[[2-(dicyclobutylamino)ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:220605 CAPLUS

DOCUMENT NUMBER: 136:263385

TITLE: Preparation of purine derivs. as adenosine A2a receptor agonists for pharmaceutical use as anti-inflammatory agents

INVENTOR(S): Mantell, Simon John; Stephenson, Peter Thomas

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022630	A1	20020321	WO 2001-IB1612	20010903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002072597	A1	20020613	US 2001-933421	20010820
AU 2001084333	A5	20020326	AU 2001-84333	20010903
PRIORITY APPLN. INFO.:			GB 2000-22695	A 20000915
			US 2000-239644P	P 20001012
			WO 2001-IB1612	W 20010903

OTHER SOURCE(S): MARPAT 136:263385

GI



AB Purine derivs., such as I [R1 = H, alkyl, arylalkyl, etc.; R2 = alkylenylsulfonylaminomethyl; R19 = C-linked heteroaryl], were prepared for therapeutic use as anti-inflammatory agents which are adenosine A2a receptor agonists for treatment of conditions, such as bronchitis, inflammatory bowel disease and peripheral vascular disease. Thus, purine II was prepared via a multistep synthetic sequence starting from (3R,4R,5R)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-2,3,4-furantriol triacetate (ester), 2-methyl-1-propanesulfonyl chloride, 2,6-dichloropurine, and 2,2-diphenylethylamine. The prepared purine derivs. were tested for anti-inflammatory activity by their ability to inhibit neutrophil function which is indicative of A2a receptor agonist activity.

IT 404935-95-1P 404935-96-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of purine derivs. as adenosine A2a receptor agonists for pharmaceutical use as antiinflammatory agents)

RN 404935-95-1 CAPLUS

CN Urea, N-[2-[cyclopentyl(1-methylethyl)amino]ethyl]-N'-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5R)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Et

RN 404935-96-2 CAPLUS

CN Urea, N-[[6-[(2,2-diphenylethyl)amino]-9-[(2R,3R,4S,5R)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-dihydroxy-2-furanyl]-9H-purin-2-yl]methyl]-N'-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 404936-06-7P 404936-07-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of purine derivs. as adenosine A2a receptor agonists for pharmaceutical use as antiinflammatory agents)

RN 404936-06-7 CAPLUS

CN Urea, N-[[9-[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl)methyl]-N'-[2-[cyclopentyl(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Et

RN 404936-07-8 CAPLUS

CN Urea, N-[[9-[(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl)methyl]-N'-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:10495 CAPLUS

DOCUMENT NUMBER: 136:70047

TITLE: Preparation of purine nucleosides as anti-inflammatory adenosine A2a receptor agonists

INVENTOR(S): Mantell, Simon John; Monaghan, Sandra Marina; Stephenson, Peter Thomas

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 176 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000676	A1	20020103	WO 2001-IB1064	20010614
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1296996	A1	20030402	EP 2001-938490	20010614
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2002032168	A1	20020314	US 2001-884244	20010619
NO 2002005975	A	20021212	NO 2002-5975	20021212
PRIORITY APPLN. INFO.:			GB 2000-15727	A 20000627
			US 2000-218466P	P 20000714
			WO 2001-IB1064	W 20010614
OTHER SOURCE(S):		MARPAT 136:70047		

GI



AB The present invention relates to purine nucleosides I wherein R1, R2 are independently H, substituted alkyl; R3 is H, alkyl, cycloalkyl, benzyl, R4 is alkyl, cycloalkyl; R3R4 together with nitrogen represent azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by alkyl or cycloalkyl; R5 is CH₂OH, substituted amide; X is CH₂, CH₂CH₂; Y is CO, CS, SO₂, C:N(CN), and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compns. containing such compds. and the uses of such compds. as adenosine A_{2a} receptor agonists. Thus, N-({9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-2-yl)methyl)-N'-[2-(diisopropylamino)ethyl]urea was prepared as adenosine A_{2a} receptor agonist. Title compds. were tested for anti-inflammatory activity by their ability to inhibit neutrophil function (which indicates A_{2a} receptor agonist activity) and all had an IC₅₀ < 1 μM.

IT 383887-24-9P 383887-26-1P 383887-28-3P
 383887-30-7P 383887-34-1P 383887-36-3P
 383887-39-6P 383887-41-0P 383887-43-2P
 383887-45-4P 383887-47-6P 383887-49-8P
 383887-51-2P 383887-53-4P 383887-55-6P
 383887-57-8P 383887-59-0P 383887-61-4P
 383887-64-7P 383887-66-9P 383887-68-1P
 383887-70-5P 383887-72-7P 383887-74-9P
 383887-76-1P 383887-78-3P 383887-80-7P
 383887-82-9P 383887-84-1P 383887-85-2P
 383887-87-4P 383887-89-6P 383887-91-0P
 383887-93-2P 383887-95-4P 383887-97-6P
 383887-99-8P 383888-01-5P 383890-96-8P


RL: BSU (Biological study, unclassified); IMF (Industrial manufacture);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)

(preparation of purine nucleosides as antiinflammatory adenosine aa receptor agonists)

RN 383887-24-9 CAPLUS

CN Adenosine, 2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-26-1 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[2-(1-piperidiny)ethyl]amino]carbonylamino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-28-3 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonylamino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-30-7 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[(2-(1-piperidinyl)ethyl)amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-34-1 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[(phenylmethyl)amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-36-3 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[(cyclohexylamino)carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-39-6 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[benzoyl(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-41-0 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[(1-methylethyl)(phenylsulfonyl)amino]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-43-2 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[methyl[2-(2-pyridinyl)ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-45-4 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-47-6 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[2-[(1-ethylpropyl)(2-methylpropyl)amino]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-49-8 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[2-[(1-ethylpropyl)(2-methylpropyl)amino]ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-51-2 CAPLUS

CN Adenosine, 2-[[[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-53-4 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[2-[[[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]amino]carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-55-6 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[2-[[[2-(dibutylamino)ethyl]amino]carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-57-8 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[cyclopentyl(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-59-0 CAPLUS

CN Adenosine, 2-[[[2-[cyclopentyl(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-61-4 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-64-7 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[cyclohexyl(1,1-dimethylethyl)amino]ethyl]amino]carbonyl]-6-[(2,2-diphenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-66-9 CAPLUS

CN Adenosine, 2-[[[2-[cyclohexyl(1,1-dimethylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-68-1 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-70-5 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-72-7 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-74-9 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[(1-methylethyl)(1-methyl-1-phenylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-76-1 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[2-[(1-methylethyl)(1-methyl-1-phenylethyl)amino]ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-78-3 CAPLUS

CN Adenosine, 2-[[[2-(dicyclopentylamino)ethyl]amino]carbonyl]amino]methyl]-N-(2,2-diphenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-80-7 CAPLUS

CN Adenosine, 2-[[[2-[[[2-bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-(9H-fluoren-9-ylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-82-9 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]amino]carbonyl]amino]methyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-84-1 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[2-[4-(1-methylethyl)-1-piperidinyl]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-85-2 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-87-4 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-89-6 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-91-0 CAPLUS

CN β -D-Ribofuranuronamide, 1-[6-[[2,2-bis(4-chlorophenyl)ethyl]amino]-2-[[[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-93-2 CAPLUS

CN Adenosine, N-[2,2-bis(4-chlorophenyl)ethyl]-2-[[[[[2-[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-95-4 CAPLUS

CN Adenosine, 2-[[[2-bis(4-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-[2,2-bis(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-97-6 CAPLUS

CN Adenosine, N-[2,2-bis(3-chlorophenyl)ethyl]-2-[[[2-bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383887-99-8 CAPLUS

CN Adenosine, 2-[[[2-[[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-N-[2,2-bis(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383888-01-5 CAPLUS

CN β -D-Ribofuranuronamide, 1-[2-[[[2-[[bis(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-6-[(1-naphthalenylmethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383890-96-8 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[methyl[[2-(1-piperidiny)ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 383888-18-4P 383888-26-4P 383888-30-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of purine nucleosides as antiinflammatory adenosine aa receptor agonists)

RN 383888-18-4 CAPLUS

CN Adenosine, N-(2,2-diphenylethyl)-2-[[[[[2-(1-piperidiny)ethyl]amino]carbonyl]amino]methyl]-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383888-26-4 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[2-[(1-methylethyl)amino]ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383888-30-0 CAPLUS

CN β -D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]methyl]-9H-purin-9-yl]-N-ethyl-, 2,3-dibenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT